About Medalchemy
Medalchemy is a Healthcare company based in Alicante (Spain) founded in 2002, and was acquired by Emmac in January 2019. Fine chemicals, APIs, and intermediates are developed and manufactured. Medalchemy offers products and services including R&D Services and APIs. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production.
Company details
Medalchemy was founded in 2002 in Alicante, Spain, where fine chemicals, active pharmaceutical ingredients (APIs), and intermediates for various therapeutic categories are developed and manufactured. Operations encompass process development, analytical development, process optimization, analytical validation, scale-up, and stability studies. The company operates within the pharmaceutical and chemical sectors, focusing on production and support services for drug-related compounds.
- Headquarters Alicante, Spain
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website medalchemy.com
- Acquired by Emmac (Jan 2019)
Products & Services of Medalchemy
Medalchemy offers a comprehensive portfolio of products and services, including R&D Services and APIs.
Provides R&D for pharmaceuticals and new chemical entities.
Develops active pharmaceutical ingredients for clinical use.
Investors in Medalchemy
Medalchemy has secured backing from 1 investor. Prominent investors backing the company include Emmac.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical cannabis products are produced and supplied by Emmac. | 2018 | emmac.com | London, United Kingdom |
Investor details for Medalchemy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Medalchemy
2 dated milestones of Medalchemy across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Medalchemy is founded.
- Exit Acquired by Emmac.
Web traffic of Medalchemy
Websites that share an audience with Medalchemy (medalchemy.com).
Websites whose visitors overlap most with Medalchemy. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| linkedin.com | 100% | 1.9B | #18 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medalchemy
Complete news archive for Medalchemy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medalchemy
Medalchemy was founded in 2002.
Medalchemy is headquartered in Alicante, Spain. It is registered at Alicante, Comunidad Valenciana, Spain.
Medalchemy was founded in 2002 in Alicante, Spain, where fine chemicals, active pharmaceutical ingredients (APIs), and intermediates for various therapeutic categories are developed and manufactured. Operations encompass process development, analytical development, process optimization, analytical validation, scale-up, and stability studies. The company operates within the pharmaceutical and chemical sectors, focusing on production and support services for drug-related compounds.
Medalchemy offers R&D Services and APIs.
Medalchemy has 1 investor. Key investors include Emmac.
Yes. Medalchemy was acquired by Emmac in January 2019.